Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Patients with rheumatoid arthritis who demonstrate consistent long-term elevation of inflammatory markers have an increased ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...